Table of Content

 Abbreviations


1          Executive Summary

 
2          Introduction & Overview

 

3          Description and Analysis

 

3.1       Characterization of Technology Companies

3.1.1    Key Features of Targeted Protein Degradation (TPD) Technologies

3.1.2    E3 Ligases & Linkers

3.1.3    Targets & Target Discovery

3.1.4    Pipeline of Targeted Protein Degraders

3.1.5    Financing & Partnering

 

3.2       Major Pharmaceutical Companies and Targeted Protein Degradation

3.2.1    TPD Drug Candidates in Development by Major Pharma Companies

3.2.2    Major Pharma’s Internal TPD Activities

3.2.2.1 Resistance to TPD

3.2.2.2 Target Proteins

3.2.2.3 Discovery Approaches

3.2.2.4 Ligase Selection & Ligase Binderss

3.2.2.5 Safety

3.2.2.6 Antibody-based Targeted Protein Degraders

3.2.2.7 PROTAC vs Molecular Glue Targeted Protein Degraders

 

4          Profiles of TPD Technology Companies

 

4.1       Amphista Therapeutics

4.2       Arvinas

4.3       BiotheryX

4.4       C4 Therapeutics

4.5       Captor Therapeutics

4.6       Cedilla Therapeutics

4.7       Cullgen

4.8       Dialectic Therapeutics

4.9       FIMECS

4.10     Hinova Pharmaceuticals

4.11     Kronos Bio

4.12     Kymera Therapeutics

4.13     Lycia Therapeutics

4.14     Monte Rosa Therapeutics

4.15     Nurix Therapeutics

4.16     Oncopia Therapeutics

4.17     Orionis Biosciences

4.18     Pin Therapeutics

4.19     Plexium

4.20     PolyProx Therapeutics

4.21     Sitryx Therapeutics

4.22     Trilo Therapeutics

4.23     Ubiquigent

4.24     Ubix Therapeutics

 

5          Profiles of Major Pharmaceutical Companies with Stakes in TPD

 

5.1       AbbVie

5.2       Amgen

5.3       AstraZeneca

5.4       Bayer

5.5       Biogen

5.6       Bristol-Myers Squibb (& Celgene)

5.7       Boehringer Ingelheim

5.8       Calico Life Sciences

5.9       Eisai

5.10.    Eli Lilly

5.11     Gilead Sciences

5.12     GlaxoSmithKline

5.13     Janssen (Johnson & Johnson)

5.14     LEO Pharma

5.15     Merck

5.16     Novartis

5.17     Pfizer

5.18     Roche

5.19     Sanofi

5.20     Vertex Pharmaceuticals

 

6          Profiles of TPD Technologies

 

6.1       PROTAC Protein Degradation (Arvinas)

6.2       Daedalus Technology Platform (C4 Therapeutics)

6.3       DELPHe Platform (Plexium)

6.4       Pegasus Technology (Kymera)

6.5       Protein Degradation by Intrinsic Pathways (Cedilla Therapeutics)

6.6       Protein Hemostatic Modulators (BioTheryX)

6.7       Targeted Protein Modulation (Nurix Therapeutics)

6.8       uSMITE Technology (Cullgen)

 

7          Profiles of Drug Candidates

 

7.1       ARV-110

7.2       ARV-471

7.3       Avadomide

7.4       CC-90009

7.5       CC-92480

7.6       DT2216

7.7       Iberdomide

7.8       KYM-001

7.9       KYM-003

7.10     NRX0492

 

8          References

Figures & Tables

Table 1           Overview of Technology Companies – Geography, Foundation & Size

Table 2           Overview of Technology Companies – TPD Technology Characterization

Table 3           Overview of Technology Companies – Technology, Source & Partnering

Table 4           Overview of Technology Companies – Funding, Pipeline & R&D Phase

Table 5           Targeted Protein Degradation Technologies and their Key Features

Table 6           Ligases Targeted by Protein Degradation Technology Companies

Table 7           Protein Targets Pursued by TPD Technology Companies

Table 8           Target Identification Technologies of TPD Technology Companies

Table 9           Pipeline of Advanced PROTAC Molecules from TPD Technology Companies

Table 10         Sources of Financing for TPD Technology Companies

Table 11         Investors of TPD Technology Companies

Table 12         Partnering Terms of Agreements between TPD Technology Companies and Major Pharmaceutical Companies

Table 13         Major Pharmaceutical Companies and Their Stakes in TPD

Table 14         Advanced Molecular Glue-like TPD Molecules

Table 15         In-House TPD Activities of Major Pharma Companies

Table 16         Protein Degradation Approaches of Celgene (BMS)